Objective: To estimate the incidence of hepatitis C virus (HCV) seroconversion and the risk of severe fibrosis/cirrhosis in HCV seroconverters among persons with human immunodeficiency virus (HIV) infection. Methods: We analysed data on 4059 persons with HIV enrolled in a cohort study in Italy. Results: Incidence rate of seroconversion was 0.6/100 person-years overall, and drug users and men-who-have-sex-with-men were at highest risk. The cumulative risk of progression to severe fibrosis/cirrhosis was 30% by 10 years after seroconversion. Conclusions: New HCV infections have a rapidly progressive course in this population. Persons with HIV and HCV superinfection should be prioritized for treatment with anti-HCV direct-acting antivirals. © 2016 European Society of Clinical Microbiology and Infectious Diseases.
- Cohort study
- Hepatitis C virus
- Human immunodeficiency virus
Puoti, M., Lorenzini, P., Lepri Cozzi, A., Gori, A., Mastroianni, C., Rizzardini, G., Mazzarello, G., Antinori, A., d'Arminio Monforte, A., & Girardi, E. (2016). Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clinical Microbiology and Infection. https://doi.org/10.1016/j.cmi.2016.12.003